Skip to main content
Premium Trial:

Request an Annual Quote

Becton Dickinson to Sell Clontech in Q2 or Q3, Official Says; Buyer Remains Undisclosed

SAN FRANCISCO, Jan. 12 (GenomeWeb News) - Becton Dickinson expects to complete the sale of its Clontech division in the second or third quarter, the company said.

 

"The process is moving ahead according to schedule," Vince Forlenza, president of BD Biosciences, said at the JPMorgan Healthcare Conference, held here this week.

 

As GenomeWeb News reported last October, BD said it plans to sell the Clontech business because it wants to "focus its strategy on cell analysis, discovery labware and its new platforms of imaging and in vitro drug metabolism/toxicity testing," Edward Ludwig, chairman, president and CEO of BD said in a statement.

The planned sale "also allows us to direct our resources toward higher-growth opportunities in the pharmaceutical drug discovery arena," Ludwig added. BD has still not disclosed the buyer.

 

BD has hired Goldman Sachs to be its financial advisor for the divestiture.

The Scan

Panel Recommends Pfizer-BioNTech Vaccine for Kids

CNN reports that the US Food and Drug Administration advisory panel has voted in favor of authorizing the Pfizer-BioNTech SARS-CoV-2 vaccine for children between 5 and 11 years old.

Sharing How to Make It

Merck had granted a royalty-free license for its COVID-19 treatment to the Medicines Patent Pool, according to the New York Times.

Bring it Back In

Bloomberg reports that a genetic analysis has tied a cluster of melioidosis cases in the US to a now-recalled aromatherapy spray.

Nucleic Acids Research Papers on SomaMutDB, VThunter, SCovid Databases

In Nucleic Acids Research this week: database of somatic mutations in normal tissue, viral receptor-related expression signatures, and more.